Dr Reddy's Laboratories enters into agreement with Merck
By Our Corporate Bureau | 01 Feb 2006
Dr Reddy’s Laboratories Ltd has entered into an agreement with Merck to sell generic versions of Merck's Proscar and Zocor, subject to a 180-day exclusivity after Merck’s patents expire for the two drugs.
Proscar is used in the treatment of benign prostatic hyperplasia (BPH) by helping to shrink the prostate in men suffering from age related prostrate growth and reduces the risk of acute urinary retention (a sudden inability to pass urine).
Zocor, Merck's top selling drug, is a statin used to lower cholesterol. Its sales during the first nine months of 2005 were $3.3 billion and Merck expects the total sales in 2005 to peak at $4.2 billion to $4.5 billion - down from $5.2 billion in 2005.
This far exceeds the $2.5 billion sales of its previous top-selling drug, Vioxx, in 2003, the drug's last full year of sales, before having to be withdrawn from the market because of its adverse side effects. Merck faces several lawsuits, projected at $50 billion.
Proscar is used in the treatment of benign prostatic hyperplasia (BPH) by helping to shrink the prostate in men suffering from age related prostrate growth and reduces the risk of acute urinary retention (a sudden inability to pass urine).
Zocor, Merck's top selling drug, is a statin used to lower cholesterol. Its sales during the first nine months of 2005 were $3.3 billion and Merck expects the total sales in 2005 to peak at $4.2 billion to $4.5 billion - down from $5.2 billion in 2005.
This far exceeds the $2.5 billion sales of its previous top-selling drug, Vioxx, in 2003, the drug's last full year of sales, before having to be withdrawn from the market because of its adverse side effects. Merck faces several lawsuits, projected at $50 billion.